The lead product of the company, Xofigo is the first marketed alpha-particle emitting radiopharmaceutics for cancer treatment.
[5] In March 2007, the company went public and traded in the Oslo Stock Exchange under the ticker symbol ALGETA and raised $41 million.
[6] Algeta’s lead product Xofigo (radium Ra 223 dichloride, radium-223, previously called Alpharadin) is a radiotherapeutic drug which is supplied as injectable sterile solution.
The product received U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)[7] approval in May 2013 [8] and November 2013,[9] respectively, to treat castration-resistant prostate cancer, symptomatic bone metastases and unknown visceral metastatic disease.
The FDA approval was based on a double-blind, randomized, placebo-controlled phase III clinical trial of 809 patients with castration-resistant prostate cancer and symptomatic bone metastases.